

## Declaration of Interests Register

**Technology Appraisal Committee A**

**Publication Date: 07/08/2019**

**Topic: Cemiplimab for treating cutaneous squamous cell carcinoma [ID1367]**

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Dr Paul Robinson	<i>TAC (A) Committee Member</i>	Indirect	Employer, Merck Sharp and Dohme make a similar product to Cemiplimab, PD1. No license pending for this indication	2017	09/04/2019	Ongoing	Declare and participate Chair: Jane Adam Associate Director: Janet Robertson
Mr Richard Ballerand	<i>TAC (A) Committee Member</i>	Indirect	Attended European Medicines Agency Scientific Advice Procedures panel as a European Patient Expert as a lay panellist for Cemiplimab	August 2018	09/04/2019	March 2019	Declare and Participate Chair: Jane Adam Associate Director: Janet Robertson  Programme Director: Helen Knight

